**Author Information** An event is serious (FDA MedWatch definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* requires intervention to prevent permanent impairment or damage

A 65-year-old man developed diffuse alveolar haemorrhage (DAH) following therapy with bevacizumab.

The man had a history of metastatic lung adenocarcinoma. He received cyclic therapy with bevacizumab \[*dosage and route not stated*\]. He presented with 3 days of dry cough and dyspnoea. He was hypoxic and tachypneic. His lung examination revealed bibasilar crackles. His upper respiratory swab was positive for coronavirus. A chest CT scan showed new, diffuse ground-glass opacities and numerous stable metastases.

The man was treated with broad-spectrum antibiotics and steroids. His condition rapidly deteriorated and he received mechanical ventilation. Bronchoalveolar lavage in the right middle lobe was increasingly bloody. A diagnosis of DAH was made \[*duration of therapy to reaction onset not stated*\]. On day 17 of the hospitalisation, he died despite escalation of steroids \[*outcome and* *cause of death not stated*\].

**Author comment:** \"*DAH should be considered as a potential complication of bevacizumab therapy in patients who develop acute respiratory symptoms and diffuse parenchymal infiltrates.*\"
